

Rare Kidney Stone Consortium Biobank

NCT02026388

| | |
|-------------------|--------------------|
| Status | RECRUITING |
| Sponsor | Mayo Clinic |
| Enrollment | 2,000 participants |

Key Eligibility Criteria

Inclusion (19)

- Diagnosis of primary hyperoxaluria (PH) meeting one or more of the following criteria:
- Liver biopsy documenting alanine-glyoxylate aminotransferase (AGT) activity below the normal reference range confirming PH type 1 OR Liver biopsy documenting glyoxylate reductase/hydroxypyruvate reductase (GR/HPR) activity below the normal reference range confirming PH type 2
- Molecular genetic analysis (DNA testing) confirming mutations known to cause PH type 1, PH type 2, or PH type 3
- Urinary oxalate excretion of greater than 0.8 mmol/1.73 m²/day (>70 mg/1.73 m²/day) in the absence of a identifiable causes of secondary hyperoxaluria, including gastrointestinal disease known to cause enteric hyperoxaluria
- A patient in end stage kidney failure, in whom neither a liver biopsy nor mutational analysis are available must have: (a) A plasma oxalate concentration of greater than 60 umol/L and a kidney biopsy confirming extensive oxalate deposits OR (b) Evidence of systemic oxalosis

... and 14 more (see full listing online)

Locations (1 total)

Mayo Clinic, Rochester, Minnesota, United States

<https://clinicaltrials.gov/study/NCT02026388>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).